Abstract Details

Title Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) S19 - (-)

Poster/Presentation
Number 006

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Elaine C. Wirrell, MD, FAAN (Mayo Clinic/Dept of Child Neurology) PRESENTER	Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Wirrell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Wirrell has received publishing royalties from a publication relating to health care.
Michael D. Privitera, MD, FAAN (Univ of Cincinnati/Dept of Neurology)	No disclosure on file
	No disclosure on file
Matthew H. Wong, MD (Matthew Wong)	No disclosure on file
J. Helen Cross (UCL-Institute of Child Health)	Dr. Cross has nothing to disclose.
Kenneth W. Sommerville, MD, FAAN	No disclosure on file